Therapy for mitochondrial disorders: Little proof, high research activity, some promise

Seminars in Fetal and Neonatal Medicine

Volumn 16, Issue 4, 2011, Pages 236-240

  Suomalainen, Anu ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Mitochondrial disease; Respiratory chain deficiency; Therapy

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; BEZAFIBRATE; CREATINE; CYTOCHROME C OXIDASE; DICHLOROACETIC ACID; IDEBENONE; METRONIDAZOLE; THIOCTIC ACID; UBIQUINONE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOACIDURIA; BONE MARROW TRANSPLANTATION; CHOLESTASIS; COCHRANE LIBRARY; CYTOCHROME C OXIDASE DEFICIENCY; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TISSUE LEVEL; ENZYME REPLACEMENT; EPILEPSY; EXERCISE; EXERCISE TOLERANCE; FAT INTAKE; GROWTH RETARDATION; HUMAN; INTESTINE FLORA; IRON OVERLOAD; KEARNS SAYRE SYNDROME; KETOGENIC DIET; LACTIC ACIDOSIS; MELAS SYNDROME; MITOCHONDRIAL ENCEPHALOMYOPATHY; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MNGIE SYNDROME; MULTIPLE ORGAN FAILURE; NEWBORN DEATH; NONHUMAN; ONSET AGE; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; RETINOPATHY; REVIEW; SUPPLEMENTATION; VITAMIN SUPPLEMENTATION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES;

EID: 79959895924     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2011.05.003     Document Type: Review

References (37)

1. Hakonen A.H., Heiskanen S., Juvonen V., et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005, 77:430-441.
2. Fellman V., Rapola J., Pihko H., Varilo T., Raivio K.O. Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, and aminoaciduria. Lancet 1998, 351:490-493.
3. Visapaa I., Fellman V., Vesa J., et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet 2002, 71:863-876.
4. Poulton J., Bredenoord A.L. 174th ENMC international workshop. Applying pre-implantation genetic diagnosis to mtDNA diseases: implications of scientific advances 19-21 March 2010, Naarden, The Netherlands. Neuromuscul Disord 2010, 20:559-563.
5. Joshi C.N., Greenberg C.R., Mhanni A.A., Salman M.S. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009, 40:314-316.
6. Kang H.C., Lee Y.M., Kim H.D., Lee J.S., Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007, 48:82-88.
7. Gillingham M.B., Weleber R.G., Neuringer M., et al. Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. Molec Genet Metab 2005, 86:124-133.
8. Gillingham M.B., Scott B., Elliott D., Harding C.O. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Molec Genet Metab 2006, 89:58-63.
9. Tiranti V., D'Adamo P., Briem E., et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet 2004, 74:239-252.
10. Tiranti V., Viscomi C., Hildebrandt T., et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med 2009, 15:200-205.
11. Viscomi C., Burlina A.B., Dweikat I., et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 2010, 16:869-871.
12. Chinnery P., Majamaa K., Turnbull D., Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006, CD004426.
13. Shults C.W., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002, 59:1541-1550.
14. Glover E.I., Martin J., Maher A., Thornhill R.E., Moran G.R., Tarnopolsky M.A. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010, 42:739-748.
15. Snow B.J., Rolfe F.L., Lockhart M.M., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010, 25:1670-1674.
16. Hassani A., Horvath R., Chinnery P.F. Mitochondrial myopathies: developments in treatment. Curr Opin Neurol 2010, 23:459-465.
17. Ogasahara S., Engel A.G., Frens D., Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989, 86:2379-2382.
18. Quinzii C.M., Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010, 16:183-188.
19. Geromel V., Darin N., Chretien D., et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab 2002, 77:21-30.
20. Lynch D.R., Perlman S.L., Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010, 67:941-947.
21. Sadun A.A., Morgia C.L., Carelli V. Leber's hereditary optic neuropathy. Curr Treat Options Neurol 2011, 13:109-117.
22. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007, 35:235-242.
23. Koga Y., Akita Y., Junko N., et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006, 66:1766-1769.
24. Koga Y., Povalko N., Nishioka J., Katayama K., Kakimoto N., Matsuishi T. MELAS and l-arginine therapy: pathophysiology of stroke-like episodes. Ann NY Acad Sci 2010, 1201:104-110.
25. Taivassalo T., Gardner J.L., Taylor R.W., et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 2006, 129:3391-3401.
26. Adhihetty P.J., Taivassalo T., Haller R.G., Walkinshaw D.R., Hood D.A. The effect of training on the expression of mitochondrial biogenesis- and apoptosis-related proteins in skeletal muscle of patients with mtDNA defects. Am J Physiol Endocrinol Metab 2007, 293:E672-E680.
27. Kaufmann P., Engelstad K., Wei Y., et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006, 66:324-330.
28. Lara M.C., Weiss B., Illa I., et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006, 67:1461-1463.
29. Yavuz H., Ozel A., Christensen M., et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 2007, 64:435-438.
30. Hirano M., Marti R., Casali C., et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006, 67:1458-1460.
31. Tyynismaa H., Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. EMBO Rep 2009, 10:137-143.
32. Tyynismaa H., Carroll C.J., Raimundo N., et al. Mitochondrial myopathy induces a starvation-like response. Hum Molec Genet 2010, Aug 11 [Epub ahead of print].
33. Ahola-Erkkila S., Carroll C.J., Peltola-Mjosund K., et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Molec Genet 2010, 19:1974-1984.
34. Safdar A., Bourgeois J.M., Ogborn D.I., et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci USA 2011, 108:4135-4140.
35. Wenz T., Diaz F., Spiegelman B.M., Moraes C.T. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008, 8:249-256.
36. Ogasawara E., Nakada K., Hayashi J. Lactic acidemia in the pathogenesis of mice carrying mitochondrial DNA with a deletion. Hum Molec Genet 2010, 19:3179-3189.
37. Trifunovic A., Hansson A., Wredenberg A., et al. Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci USA 2005, 102:17993-17998.